Citryll is pleased to announce that it has recently secured grant of patents in China (in March 2021), in Australia (in May 2021), and in the USA (in July 2021) relating to the use of therapeutic Anti-Citrullinated Protein Antibodies (tACPAs) to treat one of our lead indications, idiopathic pulmonary fibrosis (IPF).